Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
Clinical trial NCT01216696 · COMPLETED
Trial details
- NCT number
- NCT01216696
- Sponsor
- National Center for Tumor Diseases, Heidelberg
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-11-01
- Primary completion
- 2016-08-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.